Desert King® Becomes First Chilean Company to Earn EXCiPACT™ Certification, Cementing Global Leadership in Vaccine Adjuvant Production
Desert King®, a global leader in Quillaja saponaria-based vaccine adjuvants, has secured EXCiPACT™ certification for its Chilean pharmaceutical facility, becoming the first Chilean company and only global Quillaja supplier to meet rigorous GMP/GDP standards.
Desert King®, a global leader in the vaccine adjuvant market based on Quillaja saponaria saponins, is proud to announce that its Pharmaceutical Products Plant, located in the Valparaíso Region of Chile, has been awarded EXCiPACT™ certification. This milestone makes Desert King® the first company in Chile, and the only Quillaja supplier worldwide, to receive this prestigious certification—recognizing full compliance with Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) for pharmaceutical excipients.
EXCiPACT™ certification is a voluntary global standard that ensures the quality and safety of excipients used in the production of medicines. For Desert King®, this certification represents a recognition of its ongoing commitment to excellence, patient safety, and continuous improvement throughout its supply chain.
“EXCiPACT™ certification is much more than a quality standard; it is a guarantee for our clients and partners that our processes meet the most stringent international requirements. We are proud to be pioneers in Chile with this achievement, which reflects our dedication to innovation and quality in the global pharmaceutical industry,” stated Damian Hiley, Director of Desert King®.
Desert King®’s state-of-the-art production facility, dedicated specifically to manufacturing products for the pharmaceutical and diagnostics industries and now EXCiPACT™ certified, is the core site to produce ultra-purified saponin extracts — including the renowned QS-21 adjuvant, used in 5 globally approved vaccines. These include vaccines for shingles, malaria, COVID-19, and Respiratory Syncytial Virus (RSV), developed by leading pharmaceutical companies such as GSK and Novavax. As the only pharmaceutical excipient facility in Chile with both GMP and GDP standards certified under EXCiPACT™, Desert King® positions itself as a key strategic partner for pharmaceutical companies developing innovative vaccines.
Desert King® is distinguished by its leadership of more than 45 years in the field of Quillaja saponins, its commitment to the responsible and sustainable management of this unique natural resource of Chile, and its constant investment in research and development. The company not only ensures a continuous supply through its clonal plantations but also contributes to the conservation of the native Chilean forest.
With the EXCiPACT™ certification, Desert King® reaffirms its mission to offer natural solutions of the highest quality to improve global health.
We invite pharmaceutical companies seeking reliable vaccine adjuvants with international certification to learn more about our capabilities and how we can collaborate in the development of their next projects.